115 related articles for article (PubMed ID: 37606035)
21. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
[TBL] [Abstract][Full Text] [Related]
22. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Dorr RT; Liddil JD; Soble MJ
Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
[TBL] [Abstract][Full Text] [Related]
24. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
[TBL] [Abstract][Full Text] [Related]
25. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
26. Effects of the long-term depletion of reduced glutathione in mice administered L-buthionine-S,R-sulfoximine.
Sun JD; Ragsdale SS; Benson JM; Henderson RF
Fundam Appl Toxicol; 1985 Oct; 5(5):913-9. PubMed ID: 2866140
[TBL] [Abstract][Full Text] [Related]
27. Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Ong PS; Chan SY; Ho PC
Int J Oncol; 2011 Jun; 38(6):1731-9. PubMed ID: 21455570
[TBL] [Abstract][Full Text] [Related]
28. PKCδ sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage.
Marengo B; De Ciucis C; Ricciarelli R; Passalacqua M; Nitti M; Zingg JM; Marinari UM; Pronzato MA; Domenicotti C
PLoS One; 2011 Feb; 6(2):e14661. PubMed ID: 21326872
[TBL] [Abstract][Full Text] [Related]
29. Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats.
Kang YJ; Uthus EO
Biochem Pharmacol; 1996 Feb; 51(4):567-70. PubMed ID: 8619904
[TBL] [Abstract][Full Text] [Related]
30. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
[TBL] [Abstract][Full Text] [Related]
32. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
Thrall BD; Raha GA; Springer DL; Meadows GG
Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
[TBL] [Abstract][Full Text] [Related]
33. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
34. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
35. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells.
Kazimierska M; Leśniewska A; Bakker A; Diepstra A; Kasprzyk ME; Podralska M; Rassek K; Kluiver J; van den Berg A; Rozwadowska N; Dzikiewicz-Krawczyk A
J Appl Genet; 2024 Feb; 65(1):95-101. PubMed ID: 37917375
[TBL] [Abstract][Full Text] [Related]
37. The effect of in utero administration of buthionine sulfoximine on rat development.
Reyes E; Ott S; Robinson B; Contreras R
Pharmacol Biochem Behav; 1995 Apr; 50(4):491-7. PubMed ID: 7617692
[TBL] [Abstract][Full Text] [Related]
38. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
[TBL] [Abstract][Full Text] [Related]
39. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
40. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
Révész L; Edgren MR; Wainson AA
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):403-6. PubMed ID: 8195041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
